Evolus (EOLS) PT Lowered to $13 at BTIG

BTIG analyst Sam Eiber lowered the price target on Evolus (NASDAQ: EOLS) to $13.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "We are updating our EOLS model to reflect updated 2026 and long-term guidance, initially set on January 9 (see our flash note here). We think rebasing the market size and outlook (see slides 1 & 2 on pg. 4) was an appropriate step following steep declines across the aesthetic injectables category in 2025. Importantly, we heard from management that the toxin category stabilized in Q4, Jeuveau's share has reached ~14%, and that they remain committed to achieving sustainable annual profitability this year. We expect questions will remain on timing of a broader recovery in the toxin category, Jeuveau's share position in the face of new competitive entrants, and the long-term health of the filler market. We are sticking with our Buy rating but lowering our PT to $13 (from $18) after applying a 2.5x multiple on our updated 12-24 month revenue estimates."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery